Agenus Total Assets 2010-2022 | AGEN

Agenus total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Agenus Annual Total Assets
(Millions of US $)
2021 $466
2020 $215
2019 $155
2018 $136
2017 $138
2016 $157
2015 $242
2014 $75
2013 $35
2012 $29
2011 $20
2010 $31
2009 $46
Agenus Quarterly Total Assets
(Millions of US $)
2022-03-31 $441
2021-12-31 $466
2021-09-30 $438
2021-06-30 $192
2021-03-31 $235
2020-12-31 $215
2020-09-30 $204
2020-06-30 $186
2020-03-31 $180
2019-12-31 $155
2019-09-30 $175
2019-06-30 $207
2019-03-31 $246
2018-12-31 $136
2018-09-30 $130
2018-06-30 $132
2018-03-31 $131
2017-12-31 $138
2017-09-30 $149
2017-06-30 $176
2017-03-31 $203
2016-12-31 $157
2016-09-30 $175
2016-06-30 $196
2016-03-31 $221
2015-12-31 $242
2015-09-30 $243
2015-06-30 $180
2015-03-31 $117
2014-12-31 $75
2014-09-30 $88
2014-06-30 $100
2014-03-31 $108
2013-12-31 $35
2013-09-30 $38
2013-06-30 $21
2013-03-31 $25
2012-12-31 $29
2012-09-30 $32
2012-06-30 $33
2012-03-31 $33
2011-12-31 $20
2011-09-30 $24
2011-06-30 $22
2011-03-31 $26
2010-12-31 $31
2010-09-30 $37
2010-06-30 $42
2010-03-31 $39
2009-12-31 $46
2009-09-30 $51
2009-06-30 $40
2009-03-31 $47
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.406B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00